HR 890 Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Stopping Pharma’s Ripoffs and Drug Savings For All Act
To amend title 35, United States Code, to prevent double patenting, and for other purposes.
Summary
- Amends patent law to require courts to presume that pharmaceutical and biological product patents have their term disclaimed after the first patent for that product expires, unless the patent holder can prove the patents cover patentably distinct inventions
- Applies this presumption in patent validity challenges in Food and Drug Administration proceedings, Public Health Service Act proceedings, and federal district court patent litigation
- Requires the United States Patent and Trademark Office to conduct a comprehensive review of its patent examination procedures to determine whether it uses best practices to avoid issuing multiple patents on the same drug that are not patentably distinct
- Directs the USPTO to determine whether new examination practices are needed to reduce improper issuance of patents that improperly extend drug or biological product exclusivity
- Requires the USPTO Director to submit a report to Congress within one year detailing findings from the review and any recommendations for improvements
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
-
Rep. Ryan, Patrick (D-NY) [#18]
Money behind the sponsor
Top reported contributors to Patrick Ryan’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- PALANTIR TECHNOLOGIES $29,300
- WHITE & CASE LLP $22,600
- PALANTIR $19,800
- TRANSDIGM GROUP $16,500
- ANDURIL INDUSTRIES $16,500
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Patrick Ryan → · Outside spending →
Actions (2)
- Jan 31, 2025 Referred to the House Committee on the Judiciary. · house
- Jan 31, 2025 Introduced in House
Full text
IN THE HOUSE OF REPRESENTATIVES
January 31, 2025
Mr. Ryan introduced the following bill; which was referred to the Committee on the Judiciary
A BILL
To amend title 35, United States Code, to prevent double patenting, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Stopping Pharma’s Ripoffs and Drug Savings For All Act”.
SEC. 2. PREVENTION OF DOUBLE PATENTING.
(a) In General.—Section 253 of title 35, United States Code, is amended by adding at the end the following:
“(c) Disclaimers of Drug Patent Term.—
“(1) In general.—Except as provided in paragraph (2), in a proceeding challenging the validity of patents under section 505(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(c)) with respect to a drug, under section 351(l) of the Public Health Service Act (42 U.S.C. 262(l)) with respect to a biological product, or a Federal district court proceeding involving patents that are the subject of an action under section 271(e)(2), the patentee shall be presumed to have disclaimed the patent term for each of the listed patents after the date on which the term of the first patent expires, subject to the exceptions provided for in subsection (2).
“(2) Demonstration of distinct inventions.—If a patentee demonstrates by a preponderance of the evidence that certain patents described in paragraph (1) cover patentably distinct inventions from the invention claimed in the first such patent to expire, no part of the term of any such patent shall be presumed to have been disclaimed, and all patent term extensions granted by the United States Patent and Trademark Office shall be respected, unless and to the extent the patentee expressly disclaims, in writing, the patent term for each such patent.”.
(b) USPTO Review.—
(1) Definitions.—In this subsection—
(A) the term “Office” means the United States Patent and Trademark Office; and
(B) the term “Director” means the Under Secretary of Commerce for Intellectual Property and Director of the Office.
(2) Review.—The Director shall conduct a comprehensive review of the patent examination procedures of the Office to determine whether the Office—
(A) is using best examination practices, guidance, and procedures to avoid the issuance of patents relating to the same drug, or biological product, that are not patentably distinct from one another, and not subject to an appropriate disclaimer of patent term; and
(B) should develop and implement new practices, guidance, or procedures to—
(i) improve examination of patent applications relating to the same drug or biological product; and
(ii) reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.
(3) Report.—Not later than 1 year after the date of enactment of this Act, the Director shall submit to the Committee on the Judiciary of the House of Representatives a report that contains—
(A) the findings from the review conducted under paragraph (2); and
(B) any recommendations of the Director with respect to the review conducted under paragraph (2). <all>
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Comments